Review



anti human e selectin ab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems anti human e selectin ab
    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Anti Human E Selectin Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin%2FCD62E+Antibody/bio_rxiv__64898__2026__04__08__717301-188-12-15
    Average 93 stars, based on 46 article reviews
    anti human e selectin ab - by Bioz Stars, 2026-11
    93/100 stars

    Images

    1) Product Images from "CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation"

    Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

    Journal: bioRxiv

    doi: 10.64898/2026.04.08.717301

    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Figure Legend Snippet: (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

    Techniques Used: Cell Adhesion Assay, Staining, Control, Knock-Out, Negative Control, Two Tailed Test

    (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Figure Legend Snippet: (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

    Techniques Used: Injection, Isolation, Control, Two Tailed Test

    Related Articles

    In Vitro:

    Article Title: E-selectin-mediated rapid NLRP3 inflammasome activation regulates S100A8/S100A9 release from neutrophils via transient gasdermin D pore formation.
    Article Snippet: For human in vitro release assays, 5 × 105 neutrophils were stimulated with recombinant human E-selectin, recombinant human endoglycan, recombinant human MAdCAM (all 1 μg ml−1; R&D Systems) or PBS. .. For human in vitro release assays, 5 × 105 neutrophils were stimulated with recombinant human E-selectin, recombinant human endoglycan, recombinant human MAdCAM (all 1 μg ml−1; R&D Systems) or PBS. .. Quantification of intracellular S100A8/S100A9 levels Isolated bone marrow neutrophils (1 × 106 cells per 100 μl) were lysed with modified RIPA lysing buffer (150 mM NaCl, 1% Triton X-100 (Applichem), 0.5% sodium deoxycholate (Sigma-Aldrich), 50 mM Tris-HCl (pH 7.3; Merck Millipore) and 2 mM EDTA (Merck Millipore) supplemented with protease/phosphatase inhibitors (Cell Signaling) and 1× Laemmli sample buffer), homogenized and boiled (95 °C, 5 min).

    Article Title: E-selectin-mediated rapid NLRP3 inflammasome activation regulates S100A8/S100A9 release from neutrophils via transient gasdermin D pore formation
    Article Snippet: Depending on the specific groups, cells were pretreated with MCC950 (1 μM, 30 min), PAP-1 (50 nM, 10 min; Sigma-Aldrich), ibrutinib (0.6 μM, 30 min; SelleckChem) or respective vehicle controls at 37 °C and 5% CO 2 and/or stimulated with ATP (3 mM; Sigma-Aldrich), nigericin (10 μM; InvivoGen) or a combination of LPS and nigericin (1 μg ml −1 and 10 μM, respectively; both InvivoGen). .. For human in vitro release assays, 5 × 10 5 neutrophils were stimulated with recombinant human E-selectin, recombinant human endoglycan, recombinant human MAdCAM (all 1 μg ml −1 ; R&D Systems) or PBS. ..

    Recombinant:

    Article Title: E-selectin-mediated rapid NLRP3 inflammasome activation regulates S100A8/S100A9 release from neutrophils via transient gasdermin D pore formation.
    Article Snippet: For human in vitro release assays, 5 × 105 neutrophils were stimulated with recombinant human E-selectin, recombinant human endoglycan, recombinant human MAdCAM (all 1 μg ml−1; R&D Systems) or PBS. .. For human in vitro release assays, 5 × 105 neutrophils were stimulated with recombinant human E-selectin, recombinant human endoglycan, recombinant human MAdCAM (all 1 μg ml−1; R&D Systems) or PBS. .. Quantification of intracellular S100A8/S100A9 levels Isolated bone marrow neutrophils (1 × 106 cells per 100 μl) were lysed with modified RIPA lysing buffer (150 mM NaCl, 1% Triton X-100 (Applichem), 0.5% sodium deoxycholate (Sigma-Aldrich), 50 mM Tris-HCl (pH 7.3; Merck Millipore) and 2 mM EDTA (Merck Millipore) supplemented with protease/phosphatase inhibitors (Cell Signaling) and 1× Laemmli sample buffer), homogenized and boiled (95 °C, 5 min).

    Article Title: E-selectin-mediated rapid NLRP3 inflammasome activation regulates S100A8/S100A9 release from neutrophils via transient gasdermin D pore formation
    Article Snippet: Depending on the specific groups, cells were pretreated with MCC950 (1 μM, 30 min), PAP-1 (50 nM, 10 min; Sigma-Aldrich), ibrutinib (0.6 μM, 30 min; SelleckChem) or respective vehicle controls at 37 °C and 5% CO 2 and/or stimulated with ATP (3 mM; Sigma-Aldrich), nigericin (10 μM; InvivoGen) or a combination of LPS and nigericin (1 μg ml −1 and 10 μM, respectively; both InvivoGen). .. For human in vitro release assays, 5 × 10 5 neutrophils were stimulated with recombinant human E-selectin, recombinant human endoglycan, recombinant human MAdCAM (all 1 μg ml −1 ; R&D Systems) or PBS. ..

    Article Title: Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria‐related pathways in colorectal cancer
    Article Snippet: For the detection of pan‐CD44 (Diaclone, clone B‐F24, #852.601.010), CD44v3 (R&D systems, clone 3G5, #FAB5088A), CD44v4 (Novus, clone CD44v4/1219, #NBP2‐54581AF488), CD44v4/5 (R&D systems, clone 3D2, #FAB5399P), CD44v5 (Novus, clone VFF‐8, #NB100‐65533G), CD44v6 (Invitrogen, clone VFF‐7, #AHS4468), CD44v7/8 (Novus, clone VFF‐17, #NB100‐65535G) and CD44v9 (Novus, clone CD44v9/1459, #NBP2‐54571AF488), subconfluently grown TCs were detached using enzyme‐free Cell Dissociation Buffer (Gibco, #13150016). .. The expression of SLe A (Novus, clone 121SLE, #NBP2‐54349G) or static binding of recombinant human E‐selectin (rhE‐selectin/human IgG Fc chimera, R&D Systems, #724‐ES) was determined after detachment with trypsin. .. 0.5–1 × 10 6 cells were stained with aforementioned antibodies or fluorescence‐labeled E‐selectin chimera (labeled as described before, [ ]) in a final concentration of 1 μg·mL −1 in 100 μL FACS buffer (PBS −CaCl2/−MgCl2 + 1% BSA + 0.05% NaN 3 ; for E‐selectin binding PBS +CaCl2/+MgCl2 + 1% BSA + 0.05% NaN 3 ) for 15 min on ice and measured by flow cytometry (MACSQuant Analyzer 10 or Sysmex CyFlow Cube 8).

    Purification:

    Article Title: Csk-mediated Src family kinase regulation dampens neutrophil infiltration during pulmonary infection
    Article Snippet: .. Protein G–coated (500 μg/mL; EMD) glass capillaries were coated with human E-selectin (6.6 μg/mL; ADP1-050, R&D Systems) and IgG1 (25 μg/mL; BD Pharmingen) or KIM127 antibody (25 μg/mL; purified from hybridoma; ref. ) for 1 hour and blocked with 1% casein (Thermo Fisher Scientific). .. In other experiments, capillaries were coated with human P-selectin (20 μg/mL; 137-PS-050, R&D Systems), IL-8 (50 μg/mL; PeproTech), and IgG1 (5 μg/mL; Santa Cruz Biotechnology) or mAb24 (5 μg/mL; refs. ,113; gift from Nancy Hogg, Cancer Research UK London Research Institute) or CBRM1/5 antibodies (40 μg/mL; 301402, BioLegend).

    other:

    Article Title: Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria-related pathways in colorectal cancer.
    Article Snippet: For the detection of pan-CD44 (Diaclone, clone B-F24, #852.601.010), CD44v3 (R&D systems, clone 3G5, #FAB5088A), CD44v4 (Novus, clone CD44v4/ 1219, #NBP2-54581AF488), CD44v4/5 (R&D systems, clone 3D2, #FAB5399P), CD44v5 (Novus, clone VFF8, #NB100-65533G), CD44v6 (Invitrogen, clone VFF7, #AHS4468), CD44v7/8 (Novus, clone VFF-17, #NB100-65535G) and CD44v9 (Novus, clone CD44v9/ 1459, #NBP2-54571AF488), subconfluently grown TCs were detached using enzyme-free Cell Dissociation Buffer (Gibco, #13150016).

    Incubation:

    Article Title: Chemokine binding to PSGL-1 is controlled by O-glycosylation and tyrosine sulfation.
    Article Snippet: In brief Using a chemoenzymatically synthesized library of PSGL-1 N-terminus glycosulfopeptides, Goth et al. identified key roles of these posttranslational modifications on interactions between PSGL-1 and chemokines.. Using microarray, fluorescence polarization, and chemotaxis assays, they discovered that tyrosine sulfation provides favorable interactions, while complexity of O-glycans negatively affects these interactions.

    Expressing:

    Article Title: Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria‐related pathways in colorectal cancer
    Article Snippet: For the detection of pan‐CD44 (Diaclone, clone B‐F24, #852.601.010), CD44v3 (R&D systems, clone 3G5, #FAB5088A), CD44v4 (Novus, clone CD44v4/1219, #NBP2‐54581AF488), CD44v4/5 (R&D systems, clone 3D2, #FAB5399P), CD44v5 (Novus, clone VFF‐8, #NB100‐65533G), CD44v6 (Invitrogen, clone VFF‐7, #AHS4468), CD44v7/8 (Novus, clone VFF‐17, #NB100‐65535G) and CD44v9 (Novus, clone CD44v9/1459, #NBP2‐54571AF488), subconfluently grown TCs were detached using enzyme‐free Cell Dissociation Buffer (Gibco, #13150016). .. The expression of SLe A (Novus, clone 121SLE, #NBP2‐54349G) or static binding of recombinant human E‐selectin (rhE‐selectin/human IgG Fc chimera, R&D Systems, #724‐ES) was determined after detachment with trypsin. .. 0.5–1 × 10 6 cells were stained with aforementioned antibodies or fluorescence‐labeled E‐selectin chimera (labeled as described before, [ ]) in a final concentration of 1 μg·mL −1 in 100 μL FACS buffer (PBS −CaCl2/−MgCl2 + 1% BSA + 0.05% NaN 3 ; for E‐selectin binding PBS +CaCl2/+MgCl2 + 1% BSA + 0.05% NaN 3 ) for 15 min on ice and measured by flow cytometry (MACSQuant Analyzer 10 or Sysmex CyFlow Cube 8).

    Binding Assay:

    Article Title: Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria‐related pathways in colorectal cancer
    Article Snippet: For the detection of pan‐CD44 (Diaclone, clone B‐F24, #852.601.010), CD44v3 (R&D systems, clone 3G5, #FAB5088A), CD44v4 (Novus, clone CD44v4/1219, #NBP2‐54581AF488), CD44v4/5 (R&D systems, clone 3D2, #FAB5399P), CD44v5 (Novus, clone VFF‐8, #NB100‐65533G), CD44v6 (Invitrogen, clone VFF‐7, #AHS4468), CD44v7/8 (Novus, clone VFF‐17, #NB100‐65535G) and CD44v9 (Novus, clone CD44v9/1459, #NBP2‐54571AF488), subconfluently grown TCs were detached using enzyme‐free Cell Dissociation Buffer (Gibco, #13150016). .. The expression of SLe A (Novus, clone 121SLE, #NBP2‐54349G) or static binding of recombinant human E‐selectin (rhE‐selectin/human IgG Fc chimera, R&D Systems, #724‐ES) was determined after detachment with trypsin. .. 0.5–1 × 10 6 cells were stained with aforementioned antibodies or fluorescence‐labeled E‐selectin chimera (labeled as described before, [ ]) in a final concentration of 1 μg·mL −1 in 100 μL FACS buffer (PBS −CaCl2/−MgCl2 + 1% BSA + 0.05% NaN 3 ; for E‐selectin binding PBS +CaCl2/+MgCl2 + 1% BSA + 0.05% NaN 3 ) for 15 min on ice and measured by flow cytometry (MACSQuant Analyzer 10 or Sysmex CyFlow Cube 8).



    Similar Products

    94
    Shanghai Korain Biotech Co Ltd human e selectin sele elisa kit
    Human E Selectin Sele Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin/10__1186_slash_s12882___026___05349___3-52-5-11
    Average 94 stars, based on 1 article reviews
    human e selectin sele elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    RayBiotech inc human e selectin elisa kit
    Human E Selectin Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin+ELISA/pm42790593-114-23-27
    Average 94 stars, based on 1 article reviews
    human e selectin elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems anti human e selectin ab
    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Anti Human E Selectin Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin%2FCD62E+Antibody/bio_rxiv__64898__2026__04__08__717301-188-12-15
    Average 93 stars, based on 1 article reviews
    anti human e selectin ab - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    86
    Pfizer Inc human e selectin
    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Human E Selectin, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/e+human+selectin/us12577308-2310-3-7
    Average 86 stars, based on 1 article reviews
    human e selectin - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    R&D Systems e selectin
    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    E Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Recombinant+Human+E-Selectin%2FCD62E+Protein%2C+CF/us12577308-1819-20-21
    Average 94 stars, based on 1 article reviews
    e selectin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Sino Biological recombinant human p selectin
    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Recombinant Human P Selectin, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin+SELE+Protein/us12577308-2320-11-16
    Average 94 stars, based on 1 article reviews
    recombinant human p selectin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Sino Biological human e selectin
    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
    Human E Selectin, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+SELP+%2F+selectin+P+%2F+P-selectin+Protein/us12577308-2105-18-20
    Average 94 stars, based on 1 article reviews
    human e selectin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems mouse anti human p selectin
    Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial <t>cells.</t> <t>P-selectin</t> (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="250" height="auto" />
    Mouse Anti Human P Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin%2FP-Selectin+(CD62E%2FP)+APC-conjugated+Antibody/pmc13021478-120-97-100
    Average 94 stars, based on 1 article reviews
    mouse anti human p selectin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems plasma by elisa
    Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial <t>cells.</t> <t>P-selectin</t> (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="250" height="auto" />
    Plasma By Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin%2FCD62E+DuoSet+ELISA/pmc13129634-72-8-12
    Average 94 stars, based on 1 article reviews
    plasma by elisa - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems anti human p selectin
    ( A – C <t>):</t> <t>P-selectin</t> expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.
    Anti Human P Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+e+selectin/Human+E-Selectin%2FP-Selectin+(CD62E%2FP)+APC-conjugated+Antibody/pmc12943321-106-14-16
    Average 94 stars, based on 1 article reviews
    anti human p selectin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

    Journal: bioRxiv

    Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

    doi: 10.64898/2026.04.08.717301

    Figure Lengend Snippet: (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

    Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

    Techniques: Cell Adhesion Assay, Staining, Control, Knock-Out, Negative Control, Two Tailed Test

    (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

    Journal: bioRxiv

    Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

    doi: 10.64898/2026.04.08.717301

    Figure Lengend Snippet: (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

    Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

    Techniques: Injection, Isolation, Control, Two Tailed Test

    Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="100%" height="100%">

    Journal: Frontiers in Immunology

    Article Title: Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis

    doi: 10.3389/fimmu.2026.1749811

    Figure Lengend Snippet: Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to Figure 6C . Scale bar: 100 µm.

    Article Snippet: Cells were washed again and treated with the following specific antibodies: FITC-conjugated rabbit anti-human C3c-complement (Dako, that recognizes C3c, part of C3 and C3b, 1:300 final dilution in Dapi 1 μg/mL); or rabbit anti-human complement C5b-9 complex (Calbiochem, 1:200 final dilution in PBS1X) followed by FITC-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi); or goat anti-human C4 (Abcam, 1:100 final dilution in PBS1X) followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:200 final dilution in Dapi 1 μg/mL); or FITC-conjugated anti-human IgG (Sigma Aldrich, 1:32 final dilution in 1 μg/mL Dapi); or mouse anti-human P-selectin (R&D System, 20 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:60 final dilution in 1 μg/mL Dapi); or rabbit anti-human vWF (Dako, 10 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi).

    Techniques: Expressing, Control, Staining, Confocal Microscopy

    ( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

    Journal: Pathogens

    Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

    doi: 10.3390/pathogens15020196

    Figure Lengend Snippet: ( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

    Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

    Techniques: Expressing

    ( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

    Journal: Pathogens

    Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

    doi: 10.3390/pathogens15020196

    Figure Lengend Snippet: ( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

    Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

    Techniques: Clinical Proteomics